PMC:7546716 / 31382-32090 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T587","span":{"begin":222,"end":226},"obj":"Body_part"},{"id":"T588","span":{"begin":222,"end":224},"obj":"Body_part"},{"id":"T589","span":{"begin":232,"end":236},"obj":"Body_part"},{"id":"T590","span":{"begin":232,"end":234},"obj":"Body_part"},{"id":"T591","span":{"begin":255,"end":257},"obj":"Body_part"},{"id":"T592","span":{"begin":298,"end":301},"obj":"Body_part"},{"id":"T593","span":{"begin":402,"end":404},"obj":"Body_part"},{"id":"T594","span":{"begin":542,"end":544},"obj":"Body_part"},{"id":"T595","span":{"begin":551,"end":553},"obj":"Body_part"},{"id":"T596","span":{"begin":620,"end":622},"obj":"Body_part"}],"attributes":[{"id":"A587","pred":"fma_id","subj":"T587","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A588","pred":"fma_id","subj":"T588","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A589","pred":"fma_id","subj":"T589","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A590","pred":"fma_id","subj":"T590","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A591","pred":"fma_id","subj":"T591","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A592","pred":"fma_id","subj":"T592","obj":"http://purl.org/sig/ont/fma/fma20935"},{"id":"A593","pred":"fma_id","subj":"T593","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A594","pred":"fma_id","subj":"T594","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A595","pred":"fma_id","subj":"T595","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A596","pred":"fma_id","subj":"T596","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T187","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"T188","span":{"begin":435,"end":443},"obj":"Disease"}],"attributes":[{"id":"A187","pred":"mondo_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A188","pred":"mondo_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T429","span":{"begin":591,"end":593},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T456","span":{"begin":222,"end":224},"obj":"Chemical"},{"id":"T458","span":{"begin":232,"end":234},"obj":"Chemical"},{"id":"T460","span":{"begin":255,"end":257},"obj":"Chemical"},{"id":"T462","span":{"begin":295,"end":297},"obj":"Chemical"},{"id":"T463","span":{"begin":402,"end":404},"obj":"Chemical"},{"id":"T465","span":{"begin":542,"end":544},"obj":"Chemical"},{"id":"T467","span":{"begin":551,"end":553},"obj":"Chemical"},{"id":"T469","span":{"begin":620,"end":622},"obj":"Chemical"},{"id":"T471","span":{"begin":650,"end":661},"obj":"Chemical"}],"attributes":[{"id":"A456","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A457","pred":"chebi_id","subj":"T456","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A458","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A459","pred":"chebi_id","subj":"T458","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A460","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A461","pred":"chebi_id","subj":"T460","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A462","pred":"chebi_id","subj":"T462","obj":"http://purl.obolibrary.org/obo/CHEBI_74120"},{"id":"A463","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A464","pred":"chebi_id","subj":"T463","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A465","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A466","pred":"chebi_id","subj":"T465","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A467","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A468","pred":"chebi_id","subj":"T467","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A469","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A470","pred":"chebi_id","subj":"T469","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A471","pred":"chebi_id","subj":"T471","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T88","span":{"begin":255,"end":261},"obj":"http://purl.obolibrary.org/obo/GO_0005152"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-sentences","denotations":[{"id":"T134","span":{"begin":0,"end":708},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1335","span":{"begin":222,"end":227},"obj":"Gene"},{"id":"1336","span":{"begin":232,"end":237},"obj":"Gene"},{"id":"1337","span":{"begin":255,"end":261},"obj":"Gene"},{"id":"1338","span":{"begin":295,"end":301},"obj":"Gene"},{"id":"1339","span":{"begin":402,"end":406},"obj":"Gene"},{"id":"1340","span":{"begin":542,"end":546},"obj":"Gene"},{"id":"1341","span":{"begin":579,"end":587},"obj":"Species"},{"id":"1342","span":{"begin":650,"end":661},"obj":"Chemical"},{"id":"1343","span":{"begin":663,"end":672},"obj":"Chemical"},{"id":"1344","span":{"begin":184,"end":192},"obj":"Disease"},{"id":"1345","span":{"begin":435,"end":443},"obj":"Disease"}],"attributes":[{"id":"A1335","pred":"tao:has_database_id","subj":"1335","obj":"Gene:3552"},{"id":"A1336","pred":"tao:has_database_id","subj":"1336","obj":"Gene:3552"},{"id":"A1337","pred":"tao:has_database_id","subj":"1337","obj":"Gene:3557"},{"id":"A1338","pred":"tao:has_database_id","subj":"1338","obj":"Gene:1437"},{"id":"A1339","pred":"tao:has_database_id","subj":"1339","obj":"Gene:3569"},{"id":"A1340","pred":"tao:has_database_id","subj":"1340","obj":"Gene:3569"},{"id":"A1341","pred":"tao:has_database_id","subj":"1341","obj":"Tax:9606"},{"id":"A1342","pred":"tao:has_database_id","subj":"1342","obj":"MESH:C502936"},{"id":"A1343","pred":"tao:has_database_id","subj":"1343","obj":"MESH:C000592401"},{"id":"A1344","pred":"tao:has_database_id","subj":"1344","obj":"MESH:C000657245"},{"id":"A1345","pred":"tao:has_database_id","subj":"1345","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}

{"project":"2_test","denotations":[{"id":"33073244-32501454-66244638","span":{"begin":272,"end":274},"obj":"32501454"},{"id":"33073244-32411313-66244639","span":{"begin":276,"end":278},"obj":"32411313"},{"id":"33073244-32835256-66244640","span":{"begin":357,"end":359},"obj":"32835256"},{"id":"33073244-32460357-66244641","span":{"begin":487,"end":489},"obj":"32460357"},{"id":"33073244-32398875-66244642","span":{"begin":491,"end":493},"obj":"32398875"},{"id":"33073244-31986264-66244643","span":{"begin":588,"end":589},"obj":"31986264"},{"id":"33073244-32228226-66244644","span":{"begin":591,"end":593},"obj":"32228226"},{"id":"33073244-32405160-66244645","span":{"begin":698,"end":700},"obj":"32405160"}],"text":"Although more conclusive results are awaited from randomised controlled trials, encouraging preliminary results have been reported for the successful management of severe and critical COVID-19 by therapeutic modulation of IL-1α and IL-1β with recombinant IL-1RA (anakinra)84, 85 and by blocking GM-CSF using monoclonal antibodies (mavrilimumab, lenzilumab).86, 87 Although some studies have shown that IL-6 peaks at advanced stages of COVID-19 and is associated with disease severity,2, 10, 15 other studies have reported conflicting data on IL-6 and IL-6 receptor expression in patients,9, 11 and the results with anti-IL-6 receptor antibodies (eg, tocilizumab, sarilumab) have been controversial.88, 89, 90"}